Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Research analysts at Cantor Fitzgerald increased their FY2026 EPS estimates for Bristol Myers Squibb in a research note issued to investors on Wednesday, July 9th. Cantor Fitzgerald analyst C. Gould now forecasts that the biopharmaceutical company will earn $6.06 per share for the year, up from their previous estimate of $6.04. Cantor Fitzgerald currently has a "Neutral" rating and a $55.00 target price on the stock. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.74 per share.
Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The firm had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. During the same period in the prior year, the firm posted ($4.40) EPS. The firm's revenue was down 5.6% compared to the same quarter last year.
BMY has been the topic of a number of other reports. Morgan Stanley reduced their price target on shares of Bristol Myers Squibb from $36.00 to $34.00 and set an "underweight" rating on the stock in a research report on Thursday. Jefferies Financial Group reduced their price target on shares of Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. UBS Group dropped their price objective on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a report on Friday, April 11th. Argus raised shares of Bristol Myers Squibb to a "hold" rating in a report on Friday, April 25th. Finally, Piper Sandler started coverage on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Bristol Myers Squibb presently has a consensus rating of "Hold" and a consensus target price of $57.69.
Read Our Latest Stock Report on BMY
Bristol Myers Squibb Stock Down 3.3%
NYSE BMY traded down $1.61 during trading hours on Thursday, reaching $46.91. 13,670,701 shares of the company traded hands, compared to its average volume of 12,830,370. The company has a 50 day moving average of $47.51 and a two-hundred day moving average of $53.28. The company has a current ratio of 1.28, a quick ratio of 1.17 and a debt-to-equity ratio of 2.65. Bristol Myers Squibb has a 12 month low of $39.93 and a 12 month high of $63.33. The stock has a market capitalization of $95.47 billion, a PE ratio of 17.57, a PEG ratio of 2.43 and a beta of 0.36.
Bristol Myers Squibb Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be issued a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.29%. The ex-dividend date is Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio is currently 92.88%.
Insider Transactions at Bristol Myers Squibb
In other Bristol Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of Bristol Myers Squibb stock in a transaction on Friday, April 25th. The stock was purchased at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the purchase, the executive vice president directly owned 83,513 shares of the company's stock, valued at $3,973,548.54. The trade was a 5.36% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.09% of the stock is owned by company insiders.
Institutional Trading of Bristol Myers Squibb
A number of institutional investors have recently added to or reduced their stakes in the business. King Wealth Management Group lifted its stake in Bristol Myers Squibb by 2.6% in the fourth quarter. King Wealth Management Group now owns 7,294 shares of the biopharmaceutical company's stock valued at $413,000 after acquiring an additional 182 shares during the last quarter. Thoroughbred Financial Services LLC lifted its stake in Bristol Myers Squibb by 1.1% in the fourth quarter. Thoroughbred Financial Services LLC now owns 17,763 shares of the biopharmaceutical company's stock valued at $1,004,000 after acquiring an additional 190 shares during the last quarter. Marcum Wealth LLC lifted its stake in shares of Bristol Myers Squibb by 1.0% in the first quarter. Marcum Wealth LLC now owns 19,296 shares of the biopharmaceutical company's stock worth $1,177,000 after buying an additional 193 shares during the last quarter. Beacon Investment Advisory Services Inc. lifted its stake in shares of Bristol Myers Squibb by 2.7% in the first quarter. Beacon Investment Advisory Services Inc. now owns 8,063 shares of the biopharmaceutical company's stock worth $492,000 after buying an additional 212 shares during the last quarter. Finally, Leelyn Smith LLC lifted its stake in shares of Bristol Myers Squibb by 0.5% in the fourth quarter. Leelyn Smith LLC now owns 47,699 shares of the biopharmaceutical company's stock worth $2,698,000 after buying an additional 215 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.
Bristol Myers Squibb Company Profile
(
Get Free Report)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Further Reading
Before you consider Bristol Myers Squibb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.
While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
